Cellceutix Corporation
0 DAYS LEFT TO SEEK LEAD PLAINTIFF STATUS
Case Summary | |
Company Name: | Cellceutix Corporation |
Stock Symbol : | OTC: CTIX |
Class Period Start: | 05/10/2013 |
Class Period End: | 08/06/2015 |
Lead Plaintiff motion: | 11/10/2015 |
Date Filed: | 09/11/2015 |
Type of Case: | Securities Class Action |
Court: | U.S. District Court for the Southern District of New York |
Summary: | Thieler Law Corp advises investors with losses exceeding $100,000 of the November 10, 2015 lead plaintiff deadline in a class action lawsuit filed against Cellceutix Corp (OTC: CTIX) (“Cellceutix” or “the Company”). The suit is pending in the U.S. District Court for the Southern District of New York and investors, who purchased Cellceutix securities between May 10, 2013 and August 6, 2015, have until November 10, 2015 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class. If you purchased Cellceutix securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 866-6157 or emailing mail@thielerlaw.com . No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class. The complaint alleges that during the Class Period defendants made false and misleading statements and/or allegedly failed to disclose that the ineffectiveness of Cellceutix’s antibiotic drug candidate Brilacidin; Cellceutix’s anti-cancer drug candidate Kevetrin does not activate p-53 gene, which suppresses tumors; Cellceutix’s co-founder and Director, Krishna Menon, does not have a PhD in Pharmacology from Harvard University; and due to the lack of these disclosures, the Defendant’s public statements were materially false and misleading during the times specified in the complaint. On August 6, 2015, SeekingAlpha.com published a detailed report stating that Krishna Menon did not earn his PhD in Pharmacology at Harvard University as claimed, that Brilacidin is not effective, and that Kevetrin does not activate the p-53 gene as the Company claims. After the release of this report, OTC: CTIX dropped $0.73 per share or approximately 30% from its previous closing price to close at $1.71 per share on August 6, 2015. If you were negatively impacted by your investment in Cellceutix securities between May 10, 2013 and August 6, 2015 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation. Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Thieler Law Corp 2534 State Street - Suite 406, San Diego, CA 92101 by email: mail@thielerlaw.com or telephone at +1 (619) 377 - 4324 or visit our website http://www.thielerlaw.com/ or Facsimile: +1 (619) 785 – 3185 |
Please find below an excerpt of the complaint filed